AX-2025-020821

Thymalin · 10 mg declared · Chinese Peptide Company Co., Ltd. · lot CPC-2501-V2021

N/AN/A

Report ID: AX-2025-020821
Compound: Thymalin
Compound class: Short bioregulator peptides
Supplier: CPC — Chinese Peptide Company Co., Ltd.
Batch / lot: CPC-2501-V2021
Declared label claim: 10mg
Laboratory: Janoshik Analytical
Assay date: 23 Jan 2025
Submitted: 02 Feb 2025
Quarter: 2025-Q1
Submitter: ch.dahlberg
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the short bioregulator peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	not a defined quantity for this substance	N/A	—	not applicable	NOT TESTED
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	6.20	%	≤ 12.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.12	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.65	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.29	—	2.5 – 8.0	PASS

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.0	N/A
Total impurities (% area)	not stated	N/A
Largest single impurity (% area)	not stated	N/A
Water (%)	5.8	6.20
Counter-ion (%)	not stated	4.12
Peptide content (%w/w)	not stated	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (−20 °C, 7 d) → laboratory (courier, dry ice, 8 d) → assay.
Assay date: 23 Jan 2025
Submitted to the index: 02 Feb 2025
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: N/A

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
Anything expressible as a purity. This substance is not a single defined chemical entity and a purity figure for it is not a measurement. What was measured is reported above; what was not is everything a purity figure would have told you.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

ftir_amide_i02 Feb 2025

Infrared would give a secondary-structure fingerprint for Thymalin that is at least reproducible lot to lot. It is not identity, but it is more than an area percent.

sig_figs02 Feb 2025

Declared figure and measured figure on this lot agree within measurement repeatability. Whatever the rounding convention is doing, it is not moving the number away from the material.

Section 7

Related records

Same batch — lot CPC-2501-V2021 n=0

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-020822	CPC-2501-V2021	Janoshik	2025-Q1	N/A	6.68	—	Supplier-supplied	1	N/A
AX-2025-020823	CPC-2501-V2021	Janoshik	2025-Q1	N/A	6.16	—	Buyer-sourced	1	N/A
AX-2025-020824	CPC-2501-V2021	Medutest	2025-Q1	N/A	6.58	—	Buyer-sourced	1	N/A
AX-2025-020825	CPC-2501-V2021	VendorInvestigate	2025-Q1	N/A	6.67	—	Buyer-sourced	1	N/A
AX-2025-020826	CPC-2501-V2021	Janoshik	2025-Q1	N/A	6.67	—	Buyer-sourced	1	N/A
AX-2025-020827	CPC-2501-V2021	Janoshik	2025-Q1	N/A	6.64	—	Buyer-sourced	1	N/A

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Thymalin records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-020824	CPC	CPC-2501-V2021	Medutest	2025-Q1	N/A	6.58	—	Buyer-sourced	1	N/A
AX-2025-020826	CPC	CPC-2501-V2021	Janoshik	2025-Q1	N/A	6.67	—	Buyer-sourced	1	N/A
AX-2025-020822	CPC	CPC-2501-V2021	Janoshik	2025-Q1	N/A	6.68	—	Supplier-supplied	1	N/A
AX-2025-020823	CPC	CPC-2501-V2021	Janoshik	2025-Q1	N/A	6.16	—	Buyer-sourced	1	N/A
AX-2025-020825	CPC	CPC-2501-V2021	VendorInvestigate	2025-Q1	N/A	6.67	—	Buyer-sourced	1	N/A
AX-2025-020827	CPC	CPC-2501-V2021	Janoshik	2025-Q1	N/A	6.64	—	Buyer-sourced	1	N/A

Other recent CPC records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043319	BPC-157	CPC-2602-W1610	Medutest	2026-Q3	98.82	2.88	103.5	Buyer-sourced	2	MARGINAL
AX-2026-043295	Liraglutide	CPC-2602-G9942	Janoshik	2026-Q3	97.34	5.17	106.3	Buyer-sourced	0	FAIL
AX-2026-043288	Tirzepatide	CPC-2607-L1516	Janoshik	2026-Q3	96.89	5.11	101.1	Laboratory-retained	0	FAIL
AX-2026-043327	N-Acetyl Semax Amide	CPC-2602-D1905	Nordanalyt	2026-Q3	99.05	5.67	90.6	Buyer-sourced	1	FAIL
AX-2026-043328	N-Acetyl Semax Amide	CPC-2602-D1905	Janoshik	2026-Q3	99.49	6.83	100.9	Supplier-supplied	0	PASS
AX-2026-043257	L-Carnosine	CPC-2603-G9615	VendorInvestigate	2026-Q3	98.20	10.41	102.2	Buyer-sourced	0	FAIL
AX-2026-043297	Liraglutide	CPC-2602-G9942	Janoshik	2026-Q3	97.01	4.95	103.5	Buyer-sourced	0	FAIL
AX-2026-043331	N-Acetyl Semax Amide	CPC-2602-D1905	Janoshik	2026-Q3	99.46	6.22	—	Supplier-supplied	0	PASS